March 28, 2017 / 11:07 AM / 4 months ago

BRIEF-Cempra withdraws solithromycin marketing authorization application in Europe

1 Min Read

March 28 (Reuters) - Cempra Inc:

* Cempra withdraws solithromycin marketing authorization application in Europe

* Based on day 120 questions Cempra received from EMA, company believes additional data would be required

* Cempra - by withdrawing MAA at this time, it will allow co to align strategy to provide additional data to EMA, U.S. FDA to support potential approval Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below